This is a massive endorsement for MSB and REM-L. The Australian share market seems to be under-valuing this. US investors will place massive credence in Novartis backing. I suggest people look at Fate Therapeutics share price since its J&J collaboration - stem-cells in cancer. We also have a host of announcements coming that are likely postive.
Stephen Hahn will be gone from the FDA in months and things will start changing very rapidly under the new administration, Biden is an advocate of stem cell therapies, through his wife particularly.
This is a watershed moment.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-120
-
- There are more pages in this discussion • 692 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |